The Phase-2 CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen Trial (CLOVER)

This study is testing whether adding leronlimab — a drug that blocks a protein called CCR5 on cancer cells — to a standard chemotherapy combination (TAS-102 plus bevacizumab) improves outcomes for people with metastatic colorectal cancer that has already been treated with multiple prior therapies. **You may be eligible if...** - You are 18 years or older with metastatic colorectal cancer (cancer that has spread to other organs) - Your tumor has tested positive for the CCR5 protein - You have already received standard chemotherapy treatments including fluoropyrimidine, oxaliplatin, irinotecan, and anti-VEGF therapy - Your cancer is microsatellite stable (MSS) - If HIV-positive, your viral load is undetectable and you are on stable HIV treatment **You may NOT be eligible if...** - Your tumor does not express CCR5 - You have not yet received the required prior treatments - You have significant organ dysfunction - Your cancer is MSI-H (a type that responds to immunotherapy) Talk to your doctor to see if this trial is right for you.